Article
AstraZeneca's Imfinzi drug fails in head and neck cancer trial
Rating:
0.0
Views:
84
Likes:
1
Library:
1
Revenues from Imfinzi, mainly used against certain types of lung cancer, gained 42% to $1.48 billion in the first nine months of 2020, its fastest growing product.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value